The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study rationale and design
- 1 May 2003
- journal article
- clinical trial
- Published by Elsevier in Schizophrenia Research
- Vol. 61 (1) , 7-18
- https://doi.org/10.1016/s0920-9964(02)00439-5
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Prospective Diagnosis of the Initial Prodrome for Schizophrenia Based on the Structured Interview for Prodromal Syndromes: Preliminary Evidence of Interrater Reliability and Predictive ValidityAmerican Journal of Psychiatry, 2002
- Treatment of Psychosis at OnsetAmerican Journal of Psychiatry, 2002
- Shortened Duration of Untreated First Episode of Psychosis: Changes in Patient Characteristics at TreatmentAmerican Journal of Psychiatry, 2001
- Delayed Detection of Psychosis: Causes, Consequences, and Effect on Public HealthAmerican Journal of Psychiatry, 2000
- Early Detection and Intervention in Schizophrenia: ResearchSchizophrenia Bulletin, 1996
- Monitoring and Care of Young People at Incipient Risk of PsychosisSchizophrenia Bulletin, 1996
- Early Detection and Intervention in Schizophrenia: Editor's IntroductionSchizophrenia Bulletin, 1996
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A Rating Scale for Mania: Reliability, Validity and SensitivityThe British Journal of Psychiatry, 1978
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970